Registration: Free
Registration Limit: 150 people
Description: In collaboration with CKR Law, we would like to cordially invite everyone to attend a workshop and panel discussion on cross border investments and M&A to be held on February 28th. Speakers will include successful entrepreneurs, M&A attorneys, and life science investors. Topics covered will include the healthcare start-up scene in China, CFDA registration process, legal structures for entering the China market, and more. Anyone with an interest in entering the Chinese market or raising Chinese capital / collaboration in the United States will derive tremendous value from this event.
This workshop will be open for registration to everyone and is expected to fill up quickly, so register today to reserve your spot.
•Agenda:
•2:00-2:30 — Networking
•2:30-3:00 — Medical device regulations in China and the latest approaches
Speaker: Yongheng Chang
•3:00-3:30 — From science to health, an entrepreneur’s experience
Speaker: Guoliang Yu
•3:30-4:00 — The healthcare market and the environment for entrepreneurs in China
Speaker: Victor Shi
•4:00-4:30 — CFDA registration of medical devices and pharmaceuticals and the trial program with Shanghai FTZ
Speakers: Wei Zhang, Partner of CKR Law, Rong Sun, Counsel of CKR Law
•4:30-4:45 — Possible legal structures to enter into China market as a Chinese domestic company
Speaker: Ning Zhang, Partner of CKR Law (Chair of China Practice, West Coast)
•4:45-5:30 — Panel discussion (The investment outlook on cross-border biotechnology industry in 2018)
Moderator: Xu Chen
Panel members:
Tony Chen, Partner of Jones Day
Lishin Wang, CEO of Bondent Dental
Vincent Xiang, 6 Dimensions Capital
Wendy Shao, Investment & M&A, Bio-Techne Co.
Leslie Overman, Partner, CKR Law
•5:30-6:00 — Q&A and Network
Mr. Chang Yongheng, Executive Chairman of the China International Medical Device Regulatory Forum (CIMDR) -- the world’s largest annual medical device regulatory conference held by China Center for Food and Drug International Exchange (CCFDIE) of the China Food and Drug Administration (CFDA). He is also Deputy Director of the Committee for Research of Medical Device Regulation of the China Society for Drug Regulation (CSDR), Deputy Director of the Committee for Research of International Exchange and Cooperation of CSDR, Senior Member of the Chinese Pharmaceutical Association, and Chief Adviser of Ramed Bioscience Consulting, LLC.
His career started with 7 years in a medical device manufacturing company and 4 years in a pharmaceutical company. Following that, he worked in government sector for 30 years, being a Deputy Division Director in the Department of International Cooperation of SPAC (State Pharmaceutical Administration of China), Director of the Foreign Product Registration Division of the Department of Medical Devices of SPAC, Director of the Product Registration Division of the Department of Medical Devices of SFDA (State Food and Drug Administration), Deputy Counsel of the Department of Medical Devices of SFDA, and Deputy Director General of CCFDIE of CFDA successively.
His paper “Look at the Issues in the Distribution and Use of Medical Products in China with a People Oriented View” was published on “National Medical Information”, “Food and Drug Development and Administration”, “China Food and Drug Administration” and “Chinese Journal of Medicinal Guide” during 2005 - 2006. It was adopted into the large theoretical literature of “Great Practice in Implementation of the Scientific Development Concept” and appraised as the Excellent Theoretical Achievement by the China National School of Administration in 2006. Mr. Chang was rewarded with a Certificate of Honor and appointed as a Special Editor by the China National School of Administration at the same time.
Many of his papers on supervision of medical devices can be found in different journals such as the “Chinese Journal of Medicinal Guide”, “China Food and Drug Administration”, “China Medical Device Information”, “China Medical Device Journal”, “China Laboratory Medical Supplies” and “World Medical Devices”.
Dr. Guoliang Yu, Ph.D., serves as the Chairman at Jiangsu Quanxin Biopharmaceutical Co., Ltd. Dr. Yu founded QuanDx Inc. in 2010. He Co-Founded Epitomics Inc. in 2002. Dr. Yu is the Co-Founder of CBT Pharmaceuticals, Inc and serves as its Chairman of the Board. He serves as Executive Chairman of Crown Bioscience, Inc. and has been its Chief Technology Officer since August 18, 2016. Dr. Yu serves as Venture Partner at OrbiMed Advisors, L.L.C. He serves as a Consultant at Efung Capital. Dr. Yu served as the Chairman, Chief Executive Officer and President of Epitomics, Inc. He served as Senior Vice President of Research and Development at Mendel Biotechnology Inc. At Mendel Biotechnology, Dr. Yu established a robust functional genomics program, exceeded all six milestones for the Research Agreement with Monsanto and Savia and managed over 60 Ph.D. scientists and research associates. Dr. Yu worked with Human Genome Sciences, Inc., as one of the first Senior Scientists involved in the establishment of the high throughput gene discovery program. While at Human Genome Sciences, he led the technology development group and cancer group. Dr. Yu identified and characterized numerous genes for therapeutic protein and drug discovery. He contributed to the discovery of BLys. He then joined Dr. Frederick Ausubel's lab at Harvard to pursue the question how plants defend themselves against pathogens without an immune system. Dr. Yu identified the first plant disease resistance gene. In 1993, in stead of continue his academic advancement. In 1998, he was attracted to identify plant genes with economic value in agriculture and in bio-energy. Dr. Yu serves as Member of Advisory Board at DiaCarta Inc. He serves as Director at SISCAPA Assay Technologies, Inc. He serves as a Director of Applied StemCell Inc. Dr. Yu serves on the boards of several professional organizations including Bayhelix, CABS, National Foundation of Cancer Research, Chinese Biopharmaceutical Association, Ray Wu Memorial Foundation, University of Pacific in the US and China. He has more than 12 years of experience in genomics and 24 years of experience in life sciences research. Dr. Yu is involved in coaching young entrepreneurs and also serves on the board of directors for six start-up companies. He is Co-Inventor of more than 200 patents and Co-Author of over 100 patents and scientific articles and has Co-Authored 40 peer-reviewed scientific articles. Dr. Yu is the Founder of the Chinese Biopharmaceutical Association. He is one of the experts for the China's "1000 Plan."Dr. Yu was a Post-Doctoral Fellow at the Harvard Medical School. He holds a Ph.D. degree in Molecular Biology from the University of California, Berkeley and Indiana University and a B.S. degree in Biochemistry from Fudan University, Shanghai, China in 1984.
Dr. Victor Shi is Chairman of the BayHelix Group, a global association of Chinese life science business executives. Since 2017, he is Managing Partner of Serica Capital, focusing on investing in IVD and medical devices in China. Meanwhile, he is Founding President Asia Pacific of QIAGEN, a leading player of In-Vitro diagnostics and life science research service provider home and abroad.
Dr. Shi has 25 years’ experience in life science R&D, sales and marketing, business development, and investment. Previously-held positions include Managing Partner, Aura Partners, SVP of Corporate Development, Bridge Pharmaceuticals, VP of Corporate and Business Development, Genospectra (later Panomics) and Director of Asia Operations at A. M. Pappas & Associates. He was also a faculty member at National University of Singapore School of Medicine and a cancer research scientist at Merck & Co.
He is currently Vice Chair of AdvaMed China Board and Chair of its IVD Working Group. Meanwhile, he is Deputy Secretary-General of the Professional Committee of Chinese In-Vitro Diagnostics Industry Association.
Dr. Shi holds Ph.D. and M.S. degrees from the University of Rochester, New York, and a B.S. degree from the University of Science and Technology of China.
Dr. Vincent Xiang is a Partner of 6 Dimensions Capital. He has over 20 years of experience in the life sciences industries in the U.S. and China. From 2013 to 2016, Dr. Xiang was Managing Director and Head of international investments & business development at Humanwell Healthcare Group (600079.SH), which has $1.3B/year in revenue in 2015. He led the $550M acquisition of US Epic Pharma, the largest M&A ever done by a Chinese healthcare firm. Prior to that, he worked as Managing Director of Burrill Life Science Venture Capital Fund, scouting first in class assets. From 2004 to 2012, Dr. Xiang was Portfolio Manager/Analyst at Franklin Templeton, investing in global life science companies at all stages. Previously, he was Vice President of business development at Genyous, a US biotech start-up. He was also Director of venture investment at Acacia Research, Associate at BioAdvance (a healthcare Angel fund), and Irvington Fellow at Skirball Center and licensed his patented technology to Millennium Pharmaceutical for royalty payments. Dr. Xiang began his career at Sinopharm in China.
Dr. Xiang received his Ph.D. in molecular biology from University at Stony Brook, MBA from the Wharton School, and B.S. in Immunology and Microbiology from Fudan University. He is a founding member of BayHelix Group, founders and board members of two life science startups.
Tony Chen is a partner at Jones Day Shanghai office.
Tony Chen represents clients for their cross-border intellectual property and life sciences legal issues. He helps multinational companies reduce IP risks and enforce their IP rights in civil and criminal actions in China and represents Chinese companies in building and procuring intellectual property on a worldwide basis. Tony co-chairs the IP subcommittee of the American Chamber of Commerce in Shanghai and serves on the expert panel of the US – China IP Cooperation Dialogue. He has advised Shanghai Pudong District and Suzhou BioBay on the development of biopharmaceutical industry.
Mr. Lishin Wang serves as the CEO of Bondent Technology Corp, a dental equipment start up based in China. He joined the company in 2016 and is working diligently with the team to bring this local company to IPO through local expansion and global M&A.
Mr. Wang has worked in the global health care industry for 28 years with extensive experiences ranging from R&D to Sales and Marketing. He started his career in 1989 as a research scientist in the field of laser surgery, and gradually moved his career path to business management. He joined Johnson and Johnson Medical Asia Pacific in 2000 and held several senior country and regional roles, including e-Business Director of Asia Pacific, General Manager of IVD business in China, Managing Director of J&J Medical Taiwan, and North Asia Cardiology Business Director. In 2011, Mr. Wang was recruited by DAKO, a PE funded tissue based cancer diagnostic company, as the Corporate VP of Asia Pacific. The company was later acquired by Agilent in 2013. After leaving Dako, Mr. Wang joined Leica Microsystems China, A Danaher Life Science Company as the General Manager until 2016.
Mr. Wang holds an MBA degree in Finance from The Wharton School and an MS degree in Applied Physics from Georgia Institute of Technology. He also holds a US patent in photon color printing.
Dr. Shao is in charge of NASDAQ listed company Bio-Techne’s merger and acquisition and investment activities in Asia. For the past years, Bio-Techne had at least 4-5 acquisitions every year, involving companies in both China and the United States. Dr. Shao built Bio-Techne's China business ten years ago. Annual sales of Chinese operations grew from zero to RMB300 million. With the acquisition of a local Chinese firm, Bio-Techne China has fully integrated research & development, customized service and GMP manufacturing capabilities in China.
Prior to her return to China, Dr. Shao served as the director of M&A and investment of medical devices business at Guidant & Abbott Laboratories with experiences of approximately $30 billion of M&A and investment deals. She was responsible for license negotiation and intellectual property acquisition for drug stents. The global annual sales of drug eluting stent now reached more than 6 billion U.S. dollars.
Dr. Shao also oversaw early investments projects such as fully absorbable stents, cell therapies and heart valves. Many of these projects had been listed publicly or successfully exited. The $27 billion BSX/GDT/ABT deal was the largest Wall Street deals at that time. Before joining Abbott, Dr. Shao worked for Hewlett-Packard and took part in the spin-off HP's Medical Devices and Testing Group as Agilent. Agilent successful went public on NYSE and raised 2.1 billion U.S. dollars. It was the largest IPO of the year.
Ning specializes in cross-border transactions. In her close to ten-year legal career, she spent half of her time in China and half in the U.S. helping clients investing in China or U.S. through green field investment, mergers and acquisitions, joint ventures, PE/VC financing, among others. She is also experienced with commercial bank transactions in the U.S.
Selected Transactions:
•Mergers and Acquisitions
Represented a major U.S. high tech company in strategic acquisitions of various companies or assets, involving deep learning, cloud technology, CDMA business, etc.
Represented Google Capital in a proposed acquisition of an online education site in China (not closed)
Represented Hepalink, a Chinese company listed on Shenzhen Stock Exchange, in its acquisition of its competitor in the U.S. and its investment in a medical fund in the U.S.
Represented ICBC in its acquisition of a Taiwan commercial bank
Represented owners of a Chinese hospital restructure its business in a sale to a British strategic investor
Represented and participated in a number transactions where the U.S. investors disposed their interests in Chinese entities
•PE/VC Financing Deals
Represented certain medical fund in China to invest in various U.S. companies in Pre-IPO rounds
Represented a well-known U.S. pharmaceutical company in its investment in Chinese pharmaceutical companies through its fund in Asia
Represented Chinese investors in Series F investment in AirBnB and Uber
•Joint Ventures
Participated in about ten joint ventures or strategic alliance projects in various jurisdictions, including Hong Kong, Singapore, China, Cayman Islands, BVI and U.S.
•Commercial Banks
Assisted ING to form its representative office in the U.S.
Participated in more than 20 commercial banks' debt issuance or public offerings
Wei has a decade of experience in practicing intellectual property law. He advises clients on the management of U.S. and foreign IP portfolios, as well as freedom to operate, invalidity and non-infringement issues. Wei has represented clients in patent infringement and commercial litigations in the U.S. Additionally, Wei performs due diligence investigations in connection with acquisition, licensing, and technology transfer transactions, and drafts commercial agreements.
Wei was selected to the list of New York-Metro rising star for intellectual property law by Super Lawyers in years 2014-2017.
Selected Matters:
• Managed global patent portfolios for clients spanning from multinational corporations, research universities to start-ups, including Celgene Corp., Genentech, Inc., Boston Scientific Corp., etc.; and advised clients on various regulatory compliance matters.
• Represented Acorda Therapeutics, Inc. in the acquisition of a privately-held biotechnology company.
• Represented Celgene Corp. in the acquisition of a biopharmaceutical company.
• Represented Texas Instruments Inc. in a royalty obligation dispute pursuant to a patent portfolio license agreement.
• Represented a Taiwanese company in a patent infringement action relating to display technology.
• Represented a major U.S. pharmaceutical company in a patent invalidation action in Chinese patent office and courts.
• Represented a number of U.S. companies in patent interference, inter parte review, and opposition actions in the U.S., Europe, Japan, Korea, and Mexico.
Represented several start-up companies in licensing and joint venture transactions.
With decades of medical practice and hospital management experiences as well as solid legal knowledge and expertise, Ms. SUN is specialized in providing legal service to corporations and organizations of medical and pharmaceutical industry with regard to investment, incorporation, merge and acquisition and transformation.
Ms. SUN acts as outside legal counsel for a wide range of leading corporations in pharmaceutical and medical service industry, including Everjoy Health Group (SC002162), Town Health International Medical Group（HK3886）, Malo Clinic Group, Beijing Cuiyutao Children’s Healthcare Center, Landseed Medical Group, Suzhou Symap Medical Equipment Co. Ltd., Suzhou Park Medical Co. Ltd., , Shanghai Yuecheng Medical Investment and management Co. Ltd.(a wholly-owned subsidiary of CITIC PE), Shanghai Wenyi Hospital, Shanghai Chinese Medicine and Clinic Co. Ltd and Optegra Eye Health Care.
Ms. SUN participates in many joint venture establishment projects in medical service area, and some cases are pioneering in China’s medical service market. These projects include establishment and incorporation of Shanghai Guang Ci Memorial Hospital, Rui Li Plastic Surgery Hospital, Shanghai Rui Dong Hospital (Now named Parkway Health), Cascade Healthcare.
Ms SUN also possesses extensive experience in M&A, corporate restructuring and financing. She has provided legal services to many companies for their investment and M&A projects, such as the series A and B funding of Beijing Cuiyutao Children’s Healthcare Center, Malo Clinic Group, Suzhou Symap, and Serie A funding of Suzhou Park Medical.
Thanks to alliance organizations and sponsors
